Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREArtificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThe growing need to treat and prevent AD is spurring new research, but healthcare industry stakeholders need to work collaboratively if we are going to successfully bring groundbreaking treatments to market.
Alzheimer’s Disease (AD) has become an international healthcare crisis, spurring some of the greatest minds in healthcare to think more holistically about how to tackle this devastating disease. The disease affects an estimated 5.5 million Americans and is growing as our population ages; the prevalence of AD is expected triple to more than 14 million U.S. patients by 2050.
Billions have been spent on promising drug development projects over the past two decades, yielding precious few treatments that only target symptoms, and ultimately fail to slow progression.
Although the crisis is growing, so is the momentum for change. There is a renewed urgency to develop innovative drugs that treat, cure, or prevent Alzheimer’s. This passion is sparking new collaborations between patient communities, physicians, and other key stakeholders. Such collaborations are the key to finding and successfully implementing innovative solutions that address the massive unmet medical need.
Is the healthcare industry prepared to capture the opportunity and spark real change to the treatment paradigm? Our most recent white paper, A Call to Action: Alzheimer’s Disease on the Threshold of Change, identifies the five key challenges the industry will need to address to turn aspirations into action
Moving Alzheimer’s treatment forward will require significant system-wide infrastructure investment akin to the development of oncology clinics and screening initiatives that have led to the current scale of oncology treatment and diagnosis today.
The time to start thinking about the impact of new treatments – and the subsequent solutions – is now. Reimbursement and funding already present clear and present pain points. Currently, payer spending for drug costs associated with Alzheimer’s is a relatively modest slice of the total costs, which are now nearly $260B. Innovative new treatments are likely to be expensive, adding significantly to these totals. A single drug at $18,500 per patient annually, for example, would result in ~$30B in annual drug costs if used in clinical stage patients in the U.S. alone. If we include prodromal stage patients, those with initial symptoms of deteriorating memory that still function independently, overall spending on Alzheimer’s would almost double to ~$55B – and that doesn’t include related healthcare costs.
Despite the clinical and financial challenges, proactive industry leaders have an opportunity to be at the forefront of supporting the successful implementation of new Alzheimer’s treatments, helping to ensure new treatments are commercially successful, effective, affordable, and make a meaningful impact to patient’s lives. For more details on each of these challenges and the implications for clinical research and commercialization strategies, the full paper can be downloaded here.